PGP and neoplasm: Over many decades of research, no drugs have been approved as clinical P-gp blockers, although the use of small molecular inhibitors (SMIs) of P-gp to render tumor cells sensitive to chemotherapy has been widely acknowledged [22–25], with three generations of P-gp SMIs having been developed and tested in preclinical and clinical settings [26].